CC BY-NC-ND 4.0 · Endosc Int Open 2023; 11(12): E1145-E1152
DOI: 10.1055/a-2190-9303
Original article

Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia: Long-term results of endoscopic treatment

Guido Manfredi
1   Gastroenterology and Endoscopy Department, Center of reference VASCERN HHT, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Stefano Francesco Crinò
2   Digestive Endoscopy Unit, University of Verona, Italy, Verona, Italy
,
Saverio Alicante
1   Gastroenterology and Endoscopy Department, Center of reference VASCERN HHT, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Samanta Romeo
1   Gastroenterology and Endoscopy Department, Center of reference VASCERN HHT, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Roberto Berté
1   Gastroenterology and Endoscopy Department, Center of reference VASCERN HHT, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Silvia Gandolfi
3   Radiology Department, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Angelo Spinazzola
3   Radiology Department, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Michela Fiini
4   Cardiology Department, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Pierangelo Forner
5   ENT Department, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
,
Elisabetta Buscarini
1   Gastroenterology and Endoscopy Department, Center of reference VASCERN HHT, Maggiore Hospital Crema, Crema, Italy (Ringgold ID: RIN18550)
› Author Affiliations
This study has been funded with an unrestricted grant by Italian Association for Hereditary Hemorrhagic Telangiectasia "Onilde Carini". The funding body had no role in the design of the study and collection, analysis, and interpretation of data nor in writing the manuscript.

Abstract

Background and study aims This longitudinal prospective study evaluated the long-term outcome of endoscopic treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectases (HHT), its safety and outcome predictors.

Patients and methods Consecutive patients with HHT and either anemia disproportionate to epistaxis or overt gastrointestinal bleeding received endoscopic treatment of gastrointestinal telangiectases with argon plasma coagulation (APC). Hemoglobin levels and transfusion requirements were evaluated before and after treatment. Treatment effectiveness was classified as: 1) complete: hemoglobin level during the follow-up ≥9 g/dL; 2) complete with recurrence: hemoglobin ≥9 g/dL for at least 12 months with subsequent drop to <9 g/dL; or 3) absent: no improvement of hemoglobin level. Adverse events (AEs) were classified as mild, moderate, severe or fatal. Correlations were searched between treatment outcome and demographic/genetic characteristics, number, size and site of telangiectases, and hepatic arterio-venous malformations grade.

Results Forty-seven patients with HHT were enrolled. At median follow-up of 134 months (range 20–243 months), 41 of 47 patients showed treatment response (complete or with recurrence) after one (14/47) or more (27/47) endoscopic treatments. Median hemoglobin levels were 7.0 g/dL and 11.9 g/dL at baseline and at the end of follow-up, respectively. Transfusion requirement decreased from 22.8 to 7.3 red cell unit/year. A higher baseline number of telangiectases was associated with a lower chance of response (P=0.008). Only one severe AE (0.4%, jejunal perforation) was recorded.

Conclusions Endoscopic treatment of gastrointestinal teleangiectases for gastrointestinal bleeding in patients with HHT is effective in the long term and safe.

Supporting information



Publication History

Received: 01 June 2023

Accepted after revision: 04 October 2023

Accepted Manuscript online:
12 October 2023

Article published online:
15 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Shovlin CL, Buscarini E, Kjeldsen AD. et al. European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis 2018; 13: 136
  • 2 Shovlin CL, Guttmacher AE, Buscarini E. et al. Diagnostic criteria for hereditary hemorrhagic telangiectases (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67
  • 3 McDonald J, Wooderchak-Donahue W, VanSant Webb C. et al. Hereditary hemorrhagic telangiectases: genetics and molecular diagnostics in a new era. Front Genet 2015; 6: 1
  • 4 Pagan JC, Buscarini E, Janssen HLA. et al. European Association for the Study of the Liver. Vascular diseases of the liver. J Hepatol 2016; 64: 179-202
  • 5 Faughnan ME, Mager JJ, Hetts SW. et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020; 173: 989-1001
  • 6 Letteboer TG, Mager JJ, Snijder RJ. et al. Genotype-phenotype relation in hereditary hemorrhagic telangiectases. J Med Genet 2006; 43: 371-377
  • 7 Lesca G, Olivieri C, Burnichon N. et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectases: data from the French-Italian HHT network. Genet Med 2007; 9: 14-22
  • 8 Canzonieri C, Centenara L, Ornati F. et al. Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectases and correlation with their genotypes. Genet Med 2014; 16: 3-10
  • 9 Grève E, Moussata D, Gaudin JL. et al. High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectases with overt digestive bleeding and/or severe anemia. Gastrointest Endosc 2010; 71: 760-767
  • 10 Chamberlain SM, Patel J, Carter Balart J. et al. Evaluation of patients with hereditary hemorrhagic telangiectases with video capsule endoscopy: a single-center prospective study. Endoscopy 2007; 39: 516-520
  • 11 Ingrosso M, Sabbà C, Pisani A. et al. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectases: a capsule-endoscopic study. Endoscopy 2004; 36: 1074-1079
  • 12 Longacre AV, Gross CP, Gallitelli M. et al. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectases. Am J Gastroenterol 2003; 98: 59-65
  • 13 Proctor DD, Henderson KJ, Dziura JD. et al. Enteroscopic evaluation of the gastrointestinal tract in symptomatic patients with hereditary hemorrhagic telangiectases. J Clin Gastroenterol 2005; 39: 115-119
  • 14 Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectases. Am J Gastroenterol 2000; 95: 415-418
  • 15 Sargeant IR, Loizou LA, Rampton D. et al. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 1993; 34: 470-475
  • 16 Gostout CJ, Bowyer BA, Ahlquist DA. et al. Mucosal vascular malformations of the gastrointestinal tract: clinical observations and results of endoscopic neodymium: yttrium-aluminum-garnet laser therapy. Mayo Clinic proceedings 1988; 63: 993-1003
  • 17 Bown SG, Swain CP, Storey DW. et al. Endoscopic laser treatment of vascular anomalies of the upper gastrointestinal tract. Gut 1985; 26: 1338-1348
  • 18 Naveau S, Aubert A, Pynard T. et al. Long-term results of treatment of vascular malformations of the gastrointestinal tract by neodymium YAG laser photocoagulation. Dig Dis Sci 1990; 35: 821-826
  • 19 May A, Friesing-Sosnik T, Manner H. et al. Long-term outcome after argon plasma coagulation of small-bowel lesions using double-balloon enteroscopy in patients with mid-gastrointestinal bleeding. Endoscopy 2011; 43: 759-765
  • 20 Buscarini E, Buscarini L, Danesino C. et al. Hepatic vascular malformations in hereditary hemorrhagic telangiectases: Doppler sonographic screening in a large family. J Hepatol 1997; 26: 111-118
  • 21 Shovlin CL, Buscarini E, Kjeldsen AD. European Reference Network For Rare Vascular Diseases (VASCERN). et al. Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis 2018; 13: 136
  • 22 Buscarini E, Danesino C, Olivieri C. et al. Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectases -- results of extensive screening. Ultraschall Med 2004; 25: 348-355
  • 23 Buscarini E, Leandro G, Conte D. et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56: 2166-2178
  • 24 Cotton PB. Outcomes of endoscopy procedures: struggling towards definition. Gastrointest Endosc 1994; 40: 514-518
  • 25 Becq A, Rahmi G, Perrod G. et al. Hemorrhagic angiodysplasia of the digestive tract: pathogenesis, diagnosis, and management. Gastrointest Endosc 2017; 86: 792-806
  • 26 Rutgeerts P, Van Gompel F, Geboes K. et al. Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. Gut 1985; 26: 586-593